What is the PROSPER Clinical Trial?

The PROSPER Clinical Trial is a global Phase 3 clinical research trial that will include about 1500 participants. The trial will test the effects of an oral investigational drug called enzalutamide in men with non-metastatic prostate cancer that continues to progress despite hormonal therapy. The purpose of the PROSPER Clinical Trial is to compare how enzalutamide works when combined with standard treatment vs. the standard treatment only.

Join the PROSPER Clinical Trial

Do you or does someone you care about have a PSA that is continuously rising? If so, please consider taking part in the PROSPER Clinical Trial for patients with prostate cancer that has not spread beyond the prostate, but has progressed on hormonal therapy. In the PROSPER trial, patients will have a two out of three chance of being randomized to receive enzalutamide or a one in three chance of receiving placebo. All patients will receive standard treatment in addition to their respective drug/placebo assignment.

Learn more

Ask your doctor or visit [www.clinicaltrials.gov](http://www.clinicaltrials.gov) for more information (clinicaltrials.gov; Identifier NCT02003924)

You may qualify for the PROSPER Clinical Trial

- Is your PSA rising?
- Is your cancer limited to your prostate?
- Is your cancer causing no pain?
Who can join the PROSPER Clinical Trial?

Men whose prostate cancer fits this description may be able to join the PROSPER Trial:

- Your cancer has not spread beyond the prostate
- Your PSA is rising despite treatment with hormonal therapy
- Your cancer causes no pain
- Other inclusion/exclusion criteria may apply

What should you expect if you join the PROSPER Clinical Trial?

You will be asked to take your study medication capsules orally once a day. You will continue to take medication that lowers testosterone levels unless you have had an orchietomy (had your testicles removed). Two out of three trial participants will receive enzalutamide, the investigational drug being studied. One in three of the participants will receive placebo. You will be seen at the study doctor’s office one month after entering the study, 3 months later, and then every 4 months thereafter while you are taking the prostate cancer trial medication on a daily basis. At each visit, the doctor will assess how the treatment is working and whether you have any side effects. In addition to the treatment provided by the study doctor, you will continue to receive care from your current medical team.

PROSPER Clinical Trial site locations:

The PROSPER Clinical Trial is taking place at many sites worldwide.

If you believe that you or someone you care about meets the PROSPER Clinical Trial entry requirements, please speak with your doctor or visit www.clinicaltrials.gov (Identifier: NCT02003924) for a list of trial site locations.